Synovial Sarcoma clinical trials

Explore recruiting synovial sarcoma clinical trials.

Recruiting synovial sarcoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Synovial Sarcoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD 1 STUDY)

France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Pasireotide as Maintenance Treatment with monthly deep intramuscular injection in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell Tumor (PAMSARC)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Spain, Netherlands, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Prospective phase I/II trial of an individualized peptide vaccine in pediatric and AYA patients with metastasized fusion-driven sarcomas following standard treatment

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

EPITOME-1015-I: A phase I study to investigate the safety and tolerability of MDG1015 in patients with epithelial ovarian cancer, gastroesophageal adenocarcinoma, round cell liposarcoma and/or synovial sarcoma

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies

Netherlands, Spain, Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

Synovial Sarcoma trials by city

Synovial Sarcoma in Toronto Synovial Sarcoma in Vancouver Synovial Sarcoma in Montreal Synovial Sarcoma in Calgary Synovial Sarcoma in Edmonton Synovial Sarcoma in Ottawa Synovial Sarcoma in Winnipeg Synovial Sarcoma in Quebec City Synovial Sarcoma in Hamilton Synovial Sarcoma in Kitchener Synovial Sarcoma in London Synovial Sarcoma in Halifax Synovial Sarcoma in New York Synovial Sarcoma in Los Angeles Synovial Sarcoma in Chicago Synovial Sarcoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease